Ann Arbor, MI - March 6, 2025 - Genomenon, a leader in genomic intelligence, today announced the launch of an enhanced AI-powered integration for its Mastermind Genomic Intelligence Platform. This new capability further refines genomic literature search results, providing users with even more accurate and efficient access to relevant data.
Mastermind is used by leading clinical labs around the world for variant interpretation and analysis, providing comprehensive curated evidence by its team of scientific experts for genomic data, as well as indexed content from more than 10 million full-text articles. The new AI integration includes a gene disambiguation approach to build upon Mastermind's industry-leading sensitivity while introducing a new level of specificity to the literature search feature. By leveraging advanced AI technology built on the world’s leading genomic data set and expert human curation, Mastermind now offers an enhanced user experience that amplifies the platform's existing strengths.
Gene disambiguation significantly enhances the user experience by providing a more highly focused set of relevant literature on gene and variant searches. It achieves this by intelligently filtering out a substantial number of false positive full-text gene matches, allowing researchers to work with a more precise and targeted collection of articles. This capability ensures that users can be confident in the relevance of the information they are reviewing, streamlining their research process and enabling more efficient and accurate variant analysis. Importantly, while significantly improving specificity, the feature maintains Mastermind's renowned sensitivity, recovering 99.5% of true positive matches.
"Our new AI-powered integration represents a significant advancement in genomic literature analysis," said Mike Klein, CEO of Genomenon. "It enhances Mastermind's capabilities by introducing a much higher level of specificity to genomic literature searching while maintaining our industry-leading sensitivity. This innovation serves as a prime example of the practical applications and impact of our AI work. It demonstrates how, when combined with the expertise of our team of genetic scientists, our AI-driven approach can elevate variant interpretation for researchers and clinicians."
The new Mastermind AI-Integration is in production and available to all users, reinforcing Genomenon's mission to make genomic information actionable for patient care and drug discovery. This feature is powered by the advanced Genomenon Genomic Graph (G3) knowledgebase, which combines patient and biological data from nearly all published scientific and medical studies. This launch demonstrates how the company’s AI-driven solutions can enhance both the accuracy and efficiency of genomic analysis and highlights the immediate benefits of G3 and the vast potential for future applications.
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
